GDRX Goodrx Holdings Inc

GoodRx Holdings and Criteo Corp have agreed to a $32 million settlement in a class-action lawsuit. The suit alleged that the prescription pricing monitor improperly shared sensitive personal information with third-party advertising and social media sites. This settlement, if approved, significantly exceeds the fine previously recovered by the Federal Trade Commission for similar allegations.

GoodRx Holdings Inc (GDRX) reported Q3 2025 revenue of $196.0 million, surpassing estimates, but EPS missed at $0.00. The company saw significant growth in pharma manufacturer solutions revenue, increasing by 54% to $43.4 million, showcasing expanding market penetration. Despite a 9% decrease in prescription transactions revenue, GoodRx maintained its full-year revenue and adjusted EBITDA guidance, signaling confidence in its long-term strategy.

GoodRx Holdings, Inc. announced its financial results for Q4 and the full year 2024, reporting revenue of $198.6 million for Q4 and $792.3 million for the full year, a 6% increase from 2023. The company achieved a net income of $16.4 million for the full year, a significant improvement from a net loss in the previous year, and provided revenue guidance for Q1 and full year 2025. Strategic initiatives focused on capital allocation, debt reduction, and growth contributed to its performance.

This page provides live quotes and charts for GoodRx Holdings Inc. (GDRX) stock, showing its current price, daily change, and price history. It also includes an analyst ratings section, which currently indicates no available data, and states that earnings information for GoodRx Holdings Inc. is not available.

GoodRx has launched a new subscription service for men's hair loss treatment, offering affordable and convenient access to clinically proven medications like oral finasteride and minoxidil. Starting at $16/month, the service includes virtual consultations, prescriptions, and discreet home delivery, aiming to simplify access for the many men who experience hair loss. This initiative provides a transparent alternative to complex multi-product kits often seen in the market.

GoodRx (NASDAQ:GDRX) has launched a new subscription service for men's hair loss treatment, aiming to simplify access to affordable, clinically proven solutions. The service includes a virtual consultation, prescription medication, and discreet home delivery, starting as low as $16 per month. This initiative is designed to offer a straightforward alternative to complex and expensive multi-step kits often provided by competitors, providing transparent pricing and convenient delivery.